NCT04321252View on ClinicalTrials.gov

Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

July 22, 2020

Primary Completion Date

November 10, 2020

Study Completion Date

November 10, 2020

Conditions
Malaria
Interventions
DRUG

KAE609

"* iv bolus administration over approximately 2 min for doses \< 75 mg (Cohorts A1, A2 and B1)~* iv infusion over approximately 10 min for doses ≥ 75 mg (Cohorts A3, A4, A5 and B2)"

DRUG

Placebo

matching placeo for iv administration

Trial Locations (1)

B-2060

Novartis Investigative Site, Antwerp

Sponsors
All Listed Sponsors
collaborator

Wellcome Trust

OTHER

lead

Novartis Pharmaceuticals

INDUSTRY